|Dr. Michael J. Sinclair M.D.||Exec. Chairman||N/A||N/A||74|
|Dr. Roger Crystal M.D.||CEO, Pres & Director||N/A||N/A||41|
|Mr. Kevin A. Pollack J.D., Esq., M.B.A.||CFO, Treasurer & Sec.||1.17M||N/A||47|
|Dr. Phil Skolnick Ph.D., D.Sc. (hon)||Chief Scientific Officer||N/A||N/A||70|
|Mr. Quan Vu||VP of Corp. Devel.||N/A||N/A||N/A|
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops opioid antagonist treatments for addictions and related disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. It is also involved in developing treatments for binge eating disorder and cocaine use disorder, as well as Bulimia Nervosa, an eating disorder; and heroin vaccine. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. operates as a subsidiary of Pelikin Group.
Opiant Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.